Drugs / LY2780301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02018874 | Sep 2013 → Apr 2016 | non-Hodgkin lymphoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 1 | NCT01115751 | Mar 2010 → Jul 2012 | metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01980277 | Jan 2014 → May 2017 | breast cancer | Institut Paoli-Calmettes | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2780301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01115751 ↗ |
| Action | Inhibit | “LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT.” PMID 34781168 ↗ Nov 2021 |
| Route | Oral | “Administered orally” NCT01115751 ↗ |